Kedrion Biopharma Inc. Announces Advanced Manufacturing Methods Used to Further Enhance Safety Profile of Koate® Double Viral Inactivation (DVI) Antihemophilic Factor (human)

  • Company’s commitment to patients and product quality is top priority at all times
  • Process changes fortify the excellent, long-standing safety profile of Koate® Double Viral Inactivation (DVI) Antihemophilic Factor (human), a plasma-derived clotting factor
  • Enhanced pathogen-removal methods and viral inactivation steps bring even greater assurances regarding safety and purity of Koate® (DVI) Antihemophilic Factor (human)
  • Studies of the new manufacturing process showed viral reduction levels improved in six of seven viruses tested; reduction levels remained unchanged in one of the seven viruses

FORT LEE, N.J.--()--Kedrion Biopharma proudly announces that Koate® Double Viral Inactivation (DVI) Antihemophilic Factor (human) is now being manufactured using a process that further enhances the safety and purity of that product. Koate-DVI is used in the treatment of hemophilia A, a rare, inherited condition characterized by a person’s inability to form effective blood clots following an injury, and by spontaneous bleeding into one’s joints. Koate-DVI belongs to the class of products known as “plasma-derived clotting factors,” all of which are manufactured using human plasma as starting material.

The enhanced manufacturing process now used with Koate-DVI involves applying a polyethylene glycol (PEG) depth filtration step during purification of the plasma used in the production of Koate-DVI. PEG depth filtration is one of several well-established techniques used in the purification of various types of liquid material, including biologics.

Koate-DVI manufactured using the new process is currently available in 500IU and 1000IU vials, and will be introduced with 250IU vials in mid-2015.

The new process shows an enhanced ability to remove or inactivate six (6) of seven (7) viruses tested. The degree of removal and/or inactivation of the seventh virus tested remains unchanged. Another aspect of the newly enhanced process is the ability to remove low levels of a transmissible agent similar to that which causes Creutzfeldt-Jakob disease (CJD).

All plasma-derived factors are associated with a risk of viral transmission. Although there have been no documented cases of viral transmission with a Kedrion Biopharma product, including Koate-DVI, the Company and its manufacturing partners routinely engage in ongoing process improvement in all areas of its operations, remaining alert to new and improved methods to reduce even theoretical risks to patients who use its products.

“This enhancement in the manufacture of Koate-DVI is another example of the ongoing commitment to ensuring the safety of all Kedrion products,” said Garrett E. Bergman, M.D., Senior Director, Kedrion Medical Affairs. “Patients and their physicians who prescribe Koate-DVI to treat hemophilia A can now experience an added level of comfort in knowing that steps have been taken to further reduce what was initially an extremely remote risk of viral transmission. We know the hemophilia community is keenly interested in these types of activities, and we are pleased to announce such positive steps today.”

Potency of Koate-DVI remain unchanged

Studies were undertaken to determine the effect of the manufacturing enhancements on the potency of Koate-DVI. Function can be determined by assays in clotting tests, which were performed. Results indicated that Factor VIII activity and antigen, von Willebrand factor potency and antigen, overall protein content, and content of albumin, fibrinogen and IgG remain unchanged.

There are no changes to reconstitution procedures, dosing or administration.

About Koate-DVI

Koāte®-DVI, Antihemophilic Factor (Human) is a plasma-derived product for the treatment of classic hemophilia (hemophilia A), in which there is a demonstrated deficiency of the plasma clotting factor, factor VIII.

Koāte-DVI has been used to treat hemophilia A for more than 10 years, and over 1.5 billion units have been infused into patients worldwide.

Koāte-DVI contains naturally-occurring Von Willebrand factor, which is co-purified as part of the manufacturing process. Koāte-DVI has not been investigated for efficacy in the treatment of von Willebrand's disease, and hence is not approved for such usage.

Please refer to the Koate-DVI prescribing information for details.

About Hemophilia A

Hemophilia A is an inherited bleeding disorder in which a person’s blood does not clot properly. People with hemophilia A are missing or have low levels of certain clotting factors. Clotting factors are proteins that help blood clot. An effective clot is needed to seal wounds and stop bleeding. Lack of clotting factors puts a person at risk for longer bleeding episodes and other complications.

Important Safety Information for Koate-DVI

Koāte-DVI is indicated for the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma-clotting factor, factor VIII.

Koāte-DVI is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Hepatitis B vaccination is essential for patients with hemophilia A; vaccination is recommended at birth or at the time of diagnosis. Hepatitis A vaccination is also recommended for hemophilia patients who are hepatitis A seronegative.

When large or frequently repeated doses are required, patients of blood groups A, B, or AB should be monitored for signs of progressive anemia.

Allergic-type reactions may result from the administration of Antihemophilic Factor (Human) preparations. In clinical studies, adverse reactions included tingling in the arm, ear, and face, blurred vision, headache, nausea, stomach ache, and jittery feeling.

Please refer to the Koate-DVI prescribing information for details.

Individuals are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration. Visit, or call 1-800-FDA-1088.

About Kedrion

Kedrion is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, immune system deficiencies and hemolytic disease of the fetus and newborn.

Kedrion Biopharma Inc., the US subsidiary of Kedrion, is headquartered in Fort Lee, New Jersey.

Kedrion Biopharma launched US operations in 2011, but the company’s international roots stretch back several decades in the production of blood and plasma-derived products. Kedrion places a high value on not only the welfare of those who benefit from its products, but also on the people and communities it serves.

Additional information about Kedrion Biopharma can be found at

© 2015 Kedrion Biopharma Inc. All Rights Reserved. April 2015 KT-0137-00-2015


Kedrion Biopharma Inc.
Garrett Bergman, MD


Kedrion Biopharma Inc.
Garrett Bergman, MD